THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
("MyHealthChecked" or the "Company")
Comment on Share Price movement
MyHealthChecked Plc (AIM: MHC), the personalised healthcare company, notes the increase in its share price this morning, and ha s become aware of speculation over the weekend that a significant potential contract is in the pipeline.
As previously notified on 29 December 2020, the Company's COVID-19 testing service has been added to the UK Government's approved COVID-19 private testing providers list for General Testing, and the Test to Release for International Travel scheme introduced on 15 December 2020.
Whilst the Company is engaged in commercial discussions with a number of parties for the supply of COVID-19 testing kits, no contracts have been signed to date, nor is there any certainty that any of these discussions will result in commercial agreement.
As required by the AIM Rules for Companies, the Company will make further notifications as required.
MyHealthChecked plc |
|
P enny McCormick , Chief Executive Officer |
via Walbrook PR |
Maddy Kennedy, Chief Financial Officer |
|
|
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
Neil Baldwin |
|
|
|
Oberon Capital Ltd (Broker) |
Tel: +44 (0)203 179 5344 |
Mike Seabrook |
|
|
|
Walbrook PR Ltd (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com |
Paul McManus |
Mob: +44(0)7980 541 893 |